(ShareCast News) - Avacta Group established what it saw as one of the last pieces in the management puzzle to get its products towards the market, appointing professors Terence Rabbitts, Paul Moss and Adrian Hayday to form the company's scientific advisory board on Monday.The AIM-traded developer of Affimer-branded biotherapeutics and research reagents said the board would advised on and review the pre-clinical and clinical programmes for the Affimer project, as well as help guide the company's therapeutic development strategy."I am delighted to welcome Terry, Paul and Adrian on to the scientific advisory board of the company," chief executive Dr Alastair Smith said."Their individual track records speak for themselves and their appointment is the final part of our strategy to establish a leading management team, board and advisory group whose expertise will allow us to deliver the full potential of the Affimer technology for shareholders following the placing in 2015," he added.Smith said the company already had a wealth of experience and was making strong progress in the use of Affimer reagents as life science research tools, especially following the recent appointment of Dr Philippe Cotrel as chief commercial officer."Today's appointments add a world class resource to the company that will help us establish and critically review our therapeutic strategy. Together they bring the highest level of knowledge and experience and I look forward to working with them as we accelerate the development of our therapeutic programmes," he concluded.